Open AccessA phase I study of pharmacokinetics of trastuzumab emtansine in Chinese patients with locally advanced inoperable or metastatic human epidermal growth factor receptor 2-positive breast cancer who have received prior trastuzumab-based therapy
Author(s) -
Dongmei Ji,
Weina Shen,
Jian Zhang,
Junning Cao,
Wenhua Li,
Lisa H. Lam,
Fan Wu,
Bei Wang,
Zao Li,
Guofang Sun,
Xichun Hu,
ShangChiung Chen
Publication year - 2020
Publication title -
medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.59
H-Index - 148
eISSN - 1536-5964
pISSN - 0025-7974
DOI - 10.1097/md.0000000000022886
Subject(s) - medicine , trastuzumab , trastuzumab emtansine , pharmacokinetics , taxane , metastatic breast cancer , antibody drug conjugate , oncology , adverse effect , breast cancer , cmax , pharmacology , cancer , antibody , gastroenterology , immunology , monoclonal antibody